Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)


Thursday 21 January, 2021

Tissue Regenix Group

Appointment of Chief Financial Officer

RNS Number : 3879M
Tissue Regenix Group PLC
21 January 2021

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")


Appointment of Chief Financial Officer


Leeds, 21 January 2021 - Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that it has appointed David Cocke as Chief Financial Officer (CFO) and Director to the Board with immediate effect.


David has over 29 years of experience in the medical device industry holding senior finance and operations positions. In 1997, David founded NuPak Medical, an ISO-certified contract manufacturer of sterile disposable medical devices, with the Company turning cash flow positive in two years and growing the production volume from 50k to 3m over time. NuPak Medical was acquired by Katena Products, Inc. in 2017 and David remained with the business post-acquisition until early 2021, leading the expansion to double the clean room capacity and assembly space on-time and on-budget. David was also Chief Financial Officer at Aperion Biologics from 2008-2017 and supported the Board in raising $21m from venture capital and private investors. Prior to this, David was Senior Director for Finance and Operations at Kinetic Concepts from 1993-1996.


Daniel Lee, Chief Executive Officer, Tissue Regenix commented: "David is a well-respected finance professional in the medical device industry. His experience of implementing financial systems and management as well as operations, will be invaluable to the Group as we undertake the next stages of our capacity expansion programme. Having worked with David previously at Aperion Biologics I have seen first-hand the value he brings to a business and I am happy to welcome him to the Tissue Regenix Group."


Regulatory disclosure -   The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.


David Claiborne Cocke, 55, holds no ordinary shares in the Company and no options. David Cocke's current and previous directorships/partnerships are as follows:


C urrent Directorships / Partnerships

Former Directorship / Partnerships held in the last 5 years:


NuPak Medical Ltd.


Packaging Partners LC


Cetus LC


Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.


For more Information:


Tissue Regenix Group plc

Caitlin Pearson, Head of Communications


Tel: +44 (0)330 430 3052



Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price

Tel:  +44(0)20 7710 7600




Walbrook PR Ltd

Paul McManus / Alice Woodings / Lianne Cawthorne

Tel: +44 (0)20 7933 8780

[email protected]


About Tissue Regenix ( )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t